Comparative Pharmacology
Head-to-head clinical analysis: PENICILLAMINE versus VISTOGARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLAMINE versus VISTOGARD.
PENICILLAMINE vs VISTOGARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
Uridine triacetate is a prodrug of uridine, which competes with fluorouracil (5-FU) catabolites for binding to orotate phosphoribosyltransferase, reducing the incorporation of 5-FU metabolites into RNA and DNA, thereby preventing cell death.
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
6 g (2 vials) intravenously over 15 minutes as a single dose.
None Documented
None Documented
Clinical Note
moderatePenicillamine + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Eltrombopag
"The serum concentration of Eltrombopag can be increased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Iron
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
The terminal elimination half-life of uridine triacetate metabolites (primarily uridine and its metabolites) is approximately 2-3 hours. This short half-life supports the need for multiple daily doses (typically 10 doses over 5 days) to maintain therapeutic uridine concentrations.
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Vistogard (uridine triacetate) is primarily excreted via the kidneys as inactive metabolites, with approximately 90% of the administered dose recovered in urine within 24 hours. The remainder is eliminated via feces (about 10%).
Category C
Category C
Chelating Agent
Chelating Agent
"Penicillamine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy."